Vir Biotechnology, Inc. Increase (Decrease) in Other Operating Assets
Vir Biotechnology, Inc. (VIR) reported Increase (Decrease) in Other Operating Assets of -$53.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-05
- Vir Biotechnology, Inc. increase (decrease) in other operating assets for the quarter ending 2026-06-30 was $604.00K, a 91.76% decline year-over-year.
- Vir Biotechnology, Inc. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was -$657.00K.
- Vir Biotechnology, Inc. increase (decrease) in other operating assets for the quarter ending 2025-12-31 was $8.72M, a 1640.12% increase year-over-year.
- Vir Biotechnology, Inc. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was $2.79M.
- Vir Biotechnology, Inc. increase (decrease) in other operating assets for fiscal 2025 was $12.64M.
- Vir Biotechnology, Inc. increase (decrease) in other operating assets for fiscal 2024 was -$353.00K.
- Vir Biotechnology, Inc. increase (decrease) in other operating assets for fiscal 2023 was -$2.16M, a 118.32% decline from fiscal 2022.
- Vir Biotechnology, Inc. increase (decrease) in other operating assets for fiscal 2022 was $11.79M, a 695.35% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $604.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$53.00K 10-Q · filed 2026-08-05 | $8.66M derived: sum of 3 quarters · filed 2026-08-05 | $11.46M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$657.00K 10-Q · filed 2026-05-07 | $8.06M derived: sum of 2 quarters · filed 2026-05-07 | $10.85M derived: sum of 3 quarters · filed 2026-05-07 | $18.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $8.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $11.51M derived: sum of 2 quarters · filed 2026-02-23 | $18.84M derived: sum of 3 quarters · filed 2026-08-05 | $12.64M 10-K · filed 2026-02-23 |
| 2025-09-30 | $2.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $10.12M derived: sum of 2 quarters · filed 2026-08-05 | $3.92M 10-Q · filed 2025-11-05 | $4.42M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $7.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.13M 10-Q · filed 2026-08-05 | $1.63M derived: sum of 3 quarters · filed 2026-08-05 | -$103.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$6.20M 10-Q · filed 2026-05-07 | -$5.70M derived: sum of 2 quarters · filed 2026-05-07 | -$7.43M derived: sum of 3 quarters · filed 2026-05-07 | -$6.64M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $501.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$1.24M derived: sum of 2 quarters · filed 2026-02-23 | -$439.00K derived: sum of 3 quarters · filed 2026-02-23 | -$353.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | -$1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$940.00K derived: sum of 2 quarters · filed 2025-11-05 | -$854.00K 10-Q · filed 2025-11-05 | -$3.17M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $796.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $882.00K 10-Q · filed 2025-08-06 | -$1.43M derived: sum of 3 quarters · filed 2026-02-23 | -$3.56M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $86.00K 10-Q · filed 2025-05-08 | -$2.23M derived: sum of 2 quarters · filed 2026-02-23 | -$4.36M derived: sum of 3 quarters · filed 2026-02-23 | -$4.06M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | -$2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$4.44M derived: sum of 2 quarters · filed 2026-02-23 | -$4.14M derived: sum of 3 quarters · filed 2026-02-23 | -$2.16M 10-K · filed 2026-02-23 |
| 2023-09-30 | -$2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$1.83M derived: sum of 2 quarters · filed 2024-11-04 | $150.00K 10-Q · filed 2024-11-04 | $8.51M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $299.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $2.28M 10-Q · filed 2024-08-01 | $10.64M derived: sum of 3 quarters · filed 2025-02-27 | $14.04M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.98M 10-Q · filed 2024-05-03 | $10.35M derived: sum of 2 quarters · filed 2025-02-27 | $13.74M derived: sum of 3 quarters · filed 2025-02-27 | $13.55M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $8.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $11.75M derived: sum of 2 quarters · filed 2025-02-27 | $11.57M derived: sum of 3 quarters · filed 2025-02-27 | $11.79M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $3.21M derived: sum of 2 quarters · filed 2023-11-03 | $3.43M 10-Q · filed 2023-11-03 | $3.87M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$186.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $41.00K 10-Q · filed 2023-08-04 | $473.00K derived: sum of 3 quarters · filed 2024-02-26 | $667.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $227.00K 10-Q · filed 2023-05-08 | $659.00K derived: sum of 2 quarters · filed 2024-02-26 | $853.00K derived: sum of 3 quarters · filed 2024-02-26 | $1.65M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $432.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $626.00K derived: sum of 2 quarters · filed 2024-02-26 | $1.42M derived: sum of 3 quarters · filed 2024-02-26 | $1.48M 10-K · filed 2024-02-26 |
| 2021-09-30 | $194.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $988.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.05M 10-Q · filed 2022-11-03 | -$17.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $794.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $857.00K 10-Q · filed 2022-08-09 | -$211.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.60M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $63.00K 10-Q · filed 2022-05-05 | -$1.00M derived: sum of 2 quarters · filed 2023-02-28 | $802.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.04M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $739.00K derived: sum of 2 quarters · filed 2023-02-28 | $975.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.10M 10-K · filed 2023-02-28 |
| 2020-09-30 | $1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.04M derived: sum of 2 quarters · filed 2021-11-04 | $2.17M 10-Q · filed 2021-11-04 | $2.65M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $236.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $361.00K 10-Q · filed 2021-08-05 | $843.00K derived: sum of 3 quarters · filed 2022-02-28 | $2.03M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $125.00K 10-Q · filed 2021-05-06 | $607.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.79M derived: sum of 3 quarters · filed 2022-02-28 | $1.82M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $482.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.67M derived: sum of 2 quarters · filed 2022-02-28 | $1.69M derived: sum of 3 quarters · filed 2022-02-28 | $1.88M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $1.21M derived: sum of 2 quarters · filed 2020-11-10 | $1.40M 10-Q · filed 2020-11-10 | $1.09M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $212.00K 10-Q · filed 2020-08-11 | -$96.00K derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | $188.00K 10-Q · filed 2020-05-12 | -$120.00K derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | -$308.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$151.00K 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $157.00K 10-Q · filed 2019-11-19 | |||
| 2017-12-31 | $246.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |